Current Opinion in Infectious Diseases was launched in 1988. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of infectious diseases is divided into 11 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue. Section Editors Monica SlavinMonica SlavinDr Monica Slavin has been Head of the Department of Infectious Diseases at the Peter MacCallum Cancer Centre in Melbourne, Australia since 2000. She is an Associate Professor in the Department of Medicine at the University of Melbourne and a Research Associate at the Macfarlane Burnet Centre for Medical Research and Public Health. She received her medical degree from the University of Melbourne and after completing training in Infectious Diseases in Melbourne, worked for 3 years in the Program in Infectious Diseases at Fred Hutchison Cancer Research Center in Seattle, USA. She has been an Infectious Diseases physician since 1993 with a major interest in infections in immunocompromised especially patients with cancer and undergoing stem cell transplantation. Her current research focus is prevention and early treatment of invasive fungal infections in haematology patients. She has served on national steering committees for the development of antifungal and fever and neutropenia treatment guidelines and for the conduct of Australia-wide studies of the epidemiology of fungal infection. Simon CroftSimon CroftSimon Croft is Professor of Parasitology in the Faculty of Infectious and Tropical Diseases at the London School of Hygiene & Tropical Medicine, London, UK. He gained a PhD at the Liverpool School of Tropical Medicine and, after post-doctoral periods working in the laboratory on parasite ultrastructure and biochemistry and overseas on the transmission of African trypanosomiasis, he moved to research on anti-protozoal chemotherapy. His expertise and knowledge on anti-protozoal chemotherapy was developed while working with the Wellcome Research Laboratories, Beckenham, UK in the 1980 s. Following his return to academia, Simon focused his research on the identification and evaluation of novel drugs and formulations for the treatment of leishmaniasis, malaria, human African trypanosomiasis (sleeping sickness) and South American trypanosomiasis (Chagas disease). This work included projects on miltefosine, AmBisome and topical paromomycin, all of which reached clinical trials for the treatment of leishmaniasis. Other current research interests include the drug – immune response interaction and pharmacokinetics and drug delivery of antiprotozols. From 2004 to 2007 he was the Research and Development Director at the Drugs for Neglected Diseases Initiative (DNDi), Geneva. Deenan PillayDeenan PillayFollowing a PhD in Biochemistry, Dr Pillay studied Medicine in Newcastle upon Tyne and undertook postgraduate training in medical virology at St Thomas's Hospital and Royal Free Hospital, London. He was then a visiting NIH Fellow in the laboratory of Dr Doug Richman, University of California, San Diego, where he developed an interest in HIV Drug Resistance. On his return to the UK, Dr Pillay took up the post of Consultant Medical Virologist, Birmingham Public Health Laboratory and in 1996 became Director of the National PHLS Reference Laboratory for antiviral drug resistance. In 2003 he moved to University College London, with a joint appointment at the Central Public Health Laboratory, Colindale, where he is pursuing academic and epidemiological studies on drug resistance, with particular reference to HIV. Dr Pillay's main areas of interest are the treatment of viral infections and laboratory monitoring of such treatment. His current research is focused on clinical correlates of antiviral drug resistance, viral informatic approaches to antiviral drug resistance data, and epidemiology of drug resistance.